Hi my name is Linda..I live in Victoria..I was diagnosed with Chrug Strauss Syndrome in April 2005. I would really be interested in have contact with fellow sufferers for moral support...it is such a rare and pain in the butt of an autoimmune disease...i feel so isolated at times and am very desperate to communicate with other people whom are suffering from the same disease Here is a link to that at NORD for rare diseases...scroll down for links to support organizations..
http://www.rarediseases.org/search/rdbde...
Specifically here is a link to a foundation about that..
http://www.cssassociation.org/
And I believe you spelled it wrong...here is a link to clinical studies on that (in the U.S.)...hit the map button for local trials and don't forget to turn the pages.
http://www.clinicaltrials.gov/ct/search?...
I am having trouble finding a similar website to search for clinical trials in Australia, but here is an article I found.
http://rheumatology.oxfordjournals.org/c...
Here is another article of sorts...go to number 13 or look at the side for the link to Churg Strauss syndrome
http://rheumatology.oxfordjournals.org/c...
Here is a notation in WHO web of a possible link to a drug side-effect causing this..Zafirlukast is also known by the name of Accolate ...
"Zafirlukast - possible association with Churg-Strauss syndrome: United States of America "
http://www.who.int/medicinedocs/library....
Here is a notation about similar disorders (differential diagnosis) that should be tested for when you have blood work that comes out this way..
"Blood eosinophilia greater than 4% or 300-400/碌L supports the diagnosis of asthma, but an absence of this finding is not exclusionary. Eosinophil counts greater than 8% may be observed in patients with concomitant atopic dermatitis. This finding should prompt an evaluation for allergic bronchopulmonary aspergillosis, Churg-Strauss syndrome, or eosinophilic pneumonia." (in the Lab section of the article)
http://www.emedicine.com/med/topic177.ht...
Here is another reference to this drug causing this disorder.
"Adverse effects
Montelukast has been generally well tolerated in clinical trials. The adverse effects that have been reported more frequently than placebo in these clinical trials include abdominal pain and headache. Zafirlukast may cause drug interactions because it inhibits cytochrome P450, e.g. doses of warfarin may need to be reduced. Both erythromycin and theophylline reduce the plasma concentrations of zafirlukast by approximately 30-40%.
A rare disorder called Churg Strauss syndrome has occurred in 8 patients treated with zafirlukast.2 It is characterised by blood eosinophilia and eosinophilic infiltration of various organs, including skin and lung. The precise mechanism for this phenomenon is unclear, but it has been proposed that the patients had a primary eosinophilic disorder which was unmasked by the cessation (or reduction in one case) of corticosteroids when the patients began treatment with zafirlukast. Vigilance is necessary to determine if this syndrome occurs with other anti-leukotriene drugs. "
http://www.australianprescriber.com/maga...
Here is a notation about a new drug for asthma.
鈥淭he newest asthma medication is omalizumab (Xolair), a recombinant DNA-derived humanized immunoglobulin G monoclonal antibody that binds selectively to human immunoglobulin E on the surface of mast cells and basophils. The drug reduces mediator release, which promotes an allergic response. Indicated for moderate-to-severe persistent asthma in patients who react to perennial allergens, in whom symptoms are not controlled by inhaled corticosteroids. The dose (adults and children >12 y) is 150-375 mg subcutaneously every 2-4 weeks (precise dose and frequency is established by serum immunoglobulin E levels). The estimated annual cost is $12,000-15,000.
Two 52-week pivotal phase 3 clinical trials with 1071 asthma subjects were designed to study a reduction in asthma exacerbations with omalizumab. Subjects were randomized to receive subcutaneous omalizumab or placebo every 2 or 4 weeks. Inhaled corticosteroid doses were kept stable over the initial 16 weeks of treatment (stable-steroid phase) and tapered during a further 12-week treatment period (steroid-reduction phase). When used as an add-on therapy to inhaled corticosteroids, in both pivotal clinical trials, omalizumab reduced mean asthma exacerbations (ie, asthma attacks) per subject by 33-75% during the stable-steroid phase and by 33-50% during the steroid-reduction phase.鈥?(under medication section)
http://www.emedicine.com/med/topic177.ht... |
